SlideShare a Scribd company logo
Reporting Incidence of
Severe Acute Respiratory
Syndrome (SARS)
What is SARS?
• Definition:
– “Severe acute respiratory syndrome (SARS) is a viral respiratory
illness caused by a coronavirus, called SARS-associated
coronavirus (SARS-CoV).”
• Symptoms:
– high fever (> 100.4°F/ 38.0°C) at outset with
– headache, overall feeling of discomfort, & body aches
– some experience mild respiratory symptoms, diarrhea, & dry
cough.
– most develop pneumonia.
Source: US Center for Disease Control and Prevention SARS Factsheet
A Global Context
• Outbreaks of infectious diseases can
attain epidemic proportions in many
countries more quickly than in previous
centuries.
– Increased speed of travel
– Larger numbers of travelers
• Thus, limiting the spread of infectious
diseases requires a *joint effort*
Controlling Spread of Disease
• Success requires that governments:
– identify outbreaks of an infectious disease soon after
the initial cases appear
– isolate persons who have the disease or have been
in close contact with others having the disease until
they are no longer contagious
– minimize the number of non-infected persons who
come in contact with currently infected persons or any
place where germs are likely to be present
– warn other governments so they can take action to
ward off spread to their countries
The World Health Organization
• “the directing and coordinating authority for health
within the United Nations system. It is responsible for
providing leadership on global health matters, shaping
the health research agenda, setting norms and
standards, articulating evidence-based policy options,
providing technical support to countries and monitoring
and assessing health trends.”
WHO Website (emphasis added)
• in 2002-2003, WHO authority to address
outbreaks was based on the International
Health Regulations of 1969
International Health Regulations of 1969
• Regulated international cooperation to prevent spread of
disease
– BUT did not give the WHO any enforcement powers
• Required reporting outbreaks of infectious diseases
– BUT only specifically listed diseases, not any new disease likely
to spread
• Established a system of mutual assistance so that all
states could get help from WHO in identifying causes of
infection and developing methods of treatment
– BUT states were not obliged to let WHO teams visit disease-
stricken areas or have their medical labs participate in
collaborative work.
The
Outbreak
Map from Bill Marsh, The New York Times, 2003
8,141 cases in
31 countries resulting in
769 deaths at a cost of
$40 billion worldwide in
lost trade and tourism
National Responses
Compare and contrast:
• the slow and private actions of China
• the immediate actions of Vietnam
• the very public and cautious actions of
Canada
as shown on the next few slides.
SARS in China
• November 2002: Identifies “atypical pneumonia”
• February 14, 2003: Reports 305 cases and 5 deaths to WHO;
claims spread is under control
• February 18, 2003: Dr. Hong Tao concludes that the new disease
is a variant of the chlamydia virus
• February 20, 2003: Chinese Academy of Military Medical
Sciences (AMMS) researchers believe Tao’s theory is wrong;
decide to conduct further research before making public
statements
• February 21, 2003: Chinese SARS-treating doctor travels to
Hong Kong hotel; infects other guests
• early March, 2003: AMMS scientists find additional support for
coronavirus; again decide to continue research before criticizing
Government acceptance of Tao’s theory
Continued….
SARS in China
• March 10, 2003: Health Ministry requests WHO assistance
• March 21, 2003: AMMS publicly reports findings to Army
Logistical Department and Ministry of Health
• March 21, 2003: Health Ministry requests additional WHO
assistance; WHO sends 5 people
• March 25, 2003: WHO team is barred from Guangdong Province
• March 27, 2003: Guangdong Province issues guidelines on
community prevention and control
• March 28, 2003: Health Ministry grees to work with WHO
• April 3, 2003: Health Ministry allows WHO teams to visit infected
sites
• May 13, 2003: CNN International special on SARS that criticized
the Chinese government’s response to the illness is censored in
China
• End result: 7,083 cases and 644 deaths
SARS in Vietnam
• February 26, 2003: First case identified
• February 26, 2003: Asks for WHO assistance; WHO sends team
• March 6, 2003: USA sends team from Center for Disease Control
• April 29, 2003: SARS declared contained in Vietnam
• End result: 63 cases and 5 deaths
SARS in Canada
• November 27, 2002: Canadian Global Public Health Intelligence
Network (GPHIN) relays media reports of atypical pneumonia in
Guangdong Province to WHO Global Influenza Surveillance Network
• January 21, 2003: GPHIN Report is translated to English
• March 5, 2003: First case identified in Toronto
• March 17, 2003: Health Canada announces 11 cases of SARS
• April 11, 2003: Canadian Blood Services refuses donations from
persons who have been to Southeast Asia recently (even though
there is no evidence of bloodstream transfers of SARS infection)
• April 13, 2003: Michael Smith Genome Sciences Centre posts
SARS genome sequence online
• April 20, 2003: Canada's largest trauma unit stops accepting new
patients after at least four health-care workers show signs of SARS
Continued…
SARS in Canada
• April 23, 2003: WHO extends travel warnings to Toronto for 3
weeks, double the incubation time of SARS
• May 1, 2003: WHO's director of communicable-disease surveillance
and response writes an opinion article saying that the Toronto travel
advisory could ultimately harm the fight against SARS because less-
transparent countries will be afraid to report outbreaks, fearing
economic costs.
• May 14, 2003: Canada removed from WHO list of SARS-affected
countries
• May 24, 2003: Reports of new SARS cases; state of emergency
declared in Ontario; More than 500 people ordered into quarantine
in Toronto
• July 2, 2003: WHO removes Toronto from list of SARS affected
areas
• End result: 251 cases and 43 deaths
Discussion
• China, Canada and Vietnam dealt with the spread of
SARS in very different ways. Consider each country’s
approach when answering the following questions:
– Where did international regulations break down? Where did they
work?
• How would you redesign an international reporting system?
– Who asked for cooperation and who did not?
• What arguments did countries use support their decisions to, or not
to, cooperate with the WHO and other governments?
– What would you have done the same or differently
• As a bench scientist in China? in Canada?
• As a managing health official in China? in Canada?
– Who is to blame for allowing SARS to spread as far as it did?

More Related Content

What's hot

Preventive Medicine Unit 2 Slide share
Preventive Medicine Unit 2 Slide share Preventive Medicine Unit 2 Slide share
Preventive Medicine Unit 2 Slide share
CosmosTech
 
1.Definition, concepts and evaluation of public health. .ppt
1.Definition, concepts and evaluation of public health. .ppt1.Definition, concepts and evaluation of public health. .ppt
1.Definition, concepts and evaluation of public health. .ppt
Shikha Baghel Chauhan
 
Preventive medicine cholera, sars, ebola virus
Preventive medicine cholera, sars, ebola virusPreventive medicine cholera, sars, ebola virus
Preventive medicine cholera, sars, ebola virus
Ashish Chaudhari
 
Sars lec
Sars lecSars lec
Social and preventive pharmacy
Social and preventive pharmacySocial and preventive pharmacy
Social and preventive pharmacy
VarshaBarethiya
 
National AIDS Control Programme
National AIDS Control ProgrammeNational AIDS Control Programme
National AIDS Control Programme
Dr Lipilekha Patnaik
 
Social problems of sick
Social problems of sickSocial problems of sick
Social problems of sick
rajanivaddeswarapu
 
Prevention and control of dengue fever
Prevention and control of dengue feverPrevention and control of dengue fever
Prevention and control of dengue fever
Chalmeda Anandrao Institute of Medical Sciences
 
Control and prevention_of_influenza
Control and prevention_of_influenzaControl and prevention_of_influenza
Control and prevention_of_influenzaChandan N
 
Chapter 6.1 national tobacco control program
Chapter 6.1 national tobacco control programChapter 6.1 national tobacco control program
Chapter 6.1 national tobacco control program
Nilesh Kucha
 
Lymphatic filariasis
Lymphatic filariasisLymphatic filariasis
Lymphatic filariasis
Dr.Hemant Kumar
 
Role of WHO in Indian national health programs.pptx
Role of WHO in Indian national health programs.pptxRole of WHO in Indian national health programs.pptx
Role of WHO in Indian national health programs.pptx
MuralidharRaoAkkalad
 
National health intervention programme for mother and child
National health intervention programme for mother and childNational health intervention programme for mother and child
National health intervention programme for mother and child
HimikaRathi
 
Chikungunya
Chikungunya Chikungunya
Chikungunya
Dr. Shakil Ahmed
 
Safety Data Generation
Safety Data GenerationSafety Data Generation
Safety Data Generation
Dr. Ramesh Bhandari
 
Biostatistics and Research Methodology: Unit I - Measures of Central Tendency...
Biostatistics and Research Methodology: Unit I - Measures of Central Tendency...Biostatistics and Research Methodology: Unit I - Measures of Central Tendency...
Biostatistics and Research Methodology: Unit I - Measures of Central Tendency...
Chaitali Dongaonkar
 
Malaria
MalariaMalaria
Malaria
Swati Singh
 
Ebola viral disease--------- prevention
Ebola viral disease--------- preventionEbola viral disease--------- prevention
Ebola viral disease--------- preventionladdha1962
 

What's hot (20)

Preventive Medicine Unit 2 Slide share
Preventive Medicine Unit 2 Slide share Preventive Medicine Unit 2 Slide share
Preventive Medicine Unit 2 Slide share
 
1.Definition, concepts and evaluation of public health. .ppt
1.Definition, concepts and evaluation of public health. .ppt1.Definition, concepts and evaluation of public health. .ppt
1.Definition, concepts and evaluation of public health. .ppt
 
Preventive medicine cholera, sars, ebola virus
Preventive medicine cholera, sars, ebola virusPreventive medicine cholera, sars, ebola virus
Preventive medicine cholera, sars, ebola virus
 
Sars lec
Sars lecSars lec
Sars lec
 
Social and preventive pharmacy
Social and preventive pharmacySocial and preventive pharmacy
Social and preventive pharmacy
 
National AIDS Control Programme
National AIDS Control ProgrammeNational AIDS Control Programme
National AIDS Control Programme
 
Social problems of sick
Social problems of sickSocial problems of sick
Social problems of sick
 
Prevention and control of dengue fever
Prevention and control of dengue feverPrevention and control of dengue fever
Prevention and control of dengue fever
 
Cholera
CholeraCholera
Cholera
 
Control and prevention_of_influenza
Control and prevention_of_influenzaControl and prevention_of_influenza
Control and prevention_of_influenza
 
Chapter 6.1 national tobacco control program
Chapter 6.1 national tobacco control programChapter 6.1 national tobacco control program
Chapter 6.1 national tobacco control program
 
Lymphatic filariasis
Lymphatic filariasisLymphatic filariasis
Lymphatic filariasis
 
Role of WHO in Indian national health programs.pptx
Role of WHO in Indian national health programs.pptxRole of WHO in Indian national health programs.pptx
Role of WHO in Indian national health programs.pptx
 
National health intervention programme for mother and child
National health intervention programme for mother and childNational health intervention programme for mother and child
National health intervention programme for mother and child
 
Chikungunya
Chikungunya Chikungunya
Chikungunya
 
Safety Data Generation
Safety Data GenerationSafety Data Generation
Safety Data Generation
 
Biostatistics and Research Methodology: Unit I - Measures of Central Tendency...
Biostatistics and Research Methodology: Unit I - Measures of Central Tendency...Biostatistics and Research Methodology: Unit I - Measures of Central Tendency...
Biostatistics and Research Methodology: Unit I - Measures of Central Tendency...
 
Malaria
MalariaMalaria
Malaria
 
Ebola viral disease--------- prevention
Ebola viral disease--------- preventionEbola viral disease--------- prevention
Ebola viral disease--------- prevention
 
Lymphatic Filariasis jp
Lymphatic Filariasis jpLymphatic Filariasis jp
Lymphatic Filariasis jp
 

Similar to Sars updates

WHO_SARS_GLOBAL RESPONSE.ppt
WHO_SARS_GLOBAL RESPONSE.pptWHO_SARS_GLOBAL RESPONSE.ppt
WHO_SARS_GLOBAL RESPONSE.ppt
Avinash Kavi
 
Yale ESF-8 Special Report COVID-19 3-26-2020
Yale ESF-8 Special Report COVID-19 3-26-2020Yale ESF-8 Special Report COVID-19 3-26-2020
Yale ESF-8 Special Report COVID-19 3-26-2020
Yale -Tulane ESF-8 Planning and Response Network
 
Major Respritory Syndrom and COVID.pptx
Major Respritory Syndrom and COVID.pptxMajor Respritory Syndrom and COVID.pptx
Major Respritory Syndrom and COVID.pptx
Navin Kumar
 
SARS epidemiolody and morphology of the virus
SARS epidemiolody and morphology of the virusSARS epidemiolody and morphology of the virus
SARS epidemiolody and morphology of the virus
prasanna lakshmi sangineni
 
Emerging and re emerging diseases
Emerging and re emerging diseasesEmerging and re emerging diseases
Emerging and re emerging diseases
SASMITANAYAK28
 
Coronavirus webinar ppt
Coronavirus webinar ppt Coronavirus webinar ppt
Coronavirus webinar ppt
Anthony Chadwick, The Webinar Vet
 
Yale-Tulane-Sacred Heart- ESF-8 Special Global Report - COVID-19 4-27-20
Yale-Tulane-Sacred Heart- ESF-8 Special  Global Report - COVID-19 4-27-20 Yale-Tulane-Sacred Heart- ESF-8 Special  Global Report - COVID-19 4-27-20
Yale-Tulane-Sacred Heart- ESF-8 Special Global Report - COVID-19 4-27-20
Yale -Tulane ESF-8 Planning and Response Network
 
Overview of COVID-19
Overview of COVID-19Overview of COVID-19
Overview of COVID-19
Adaiah
 
Yale-Tulane Special Report - MERS-CoV 26 APRIL 2014
Yale-Tulane Special Report  - MERS-CoV 26 APRIL 2014Yale-Tulane Special Report  - MERS-CoV 26 APRIL 2014
Yale-Tulane Special Report - MERS-CoV 26 APRIL 2014
Yale -Tulane ESF-8 Planning and Response Network
 
120130 the sars experience
120130   the sars experience120130   the sars experience
120130 the sars experienceAnnita Mau
 
Epidemiology basic concepts,scope,uses, consideration, components ,history an...
Epidemiology basic concepts,scope,uses, consideration, components ,history an...Epidemiology basic concepts,scope,uses, consideration, components ,history an...
Epidemiology basic concepts,scope,uses, consideration, components ,history an...
tanvirahm1220
 
SURVEILLANCE OF HEALTH EVENT
SURVEILLANCE OF HEALTH EVENTSURVEILLANCE OF HEALTH EVENT
SURVEILLANCE OF HEALTH EVENT
Aneesa K Ayoob
 
Yale- Tulane-Sacred Heart ESF-8 Special US Report - COVID-19 5-1-20
Yale- Tulane-Sacred Heart ESF-8 Special US Report - COVID-19  5-1-20Yale- Tulane-Sacred Heart ESF-8 Special US Report - COVID-19  5-1-20
Yale- Tulane-Sacred Heart ESF-8 Special US Report - COVID-19 5-1-20
Yale -Tulane ESF-8 Planning and Response Network
 
Fight against SARS
Fight against SARS Fight against SARS
Fight against SARS
Akash Wallepure
 
Week 4 Week 4 - Epidemiology—IntroductionEpidemiology—Introdu.docx
Week 4 Week 4 - Epidemiology—IntroductionEpidemiology—Introdu.docxWeek 4 Week 4 - Epidemiology—IntroductionEpidemiology—Introdu.docx
Week 4 Week 4 - Epidemiology—IntroductionEpidemiology—Introdu.docx
melbruce90096
 
Lecture 1 epidemiology.pptx2222222222222
Lecture 1 epidemiology.pptx2222222222222Lecture 1 epidemiology.pptx2222222222222
Lecture 1 epidemiology.pptx2222222222222
KelfalaHassanDawoh
 
Epidemic Investigation.pdf
Epidemic Investigation.pdfEpidemic Investigation.pdf
Epidemic Investigation.pdf
DinaOmer4
 
1. Epidemiology_Lecture_07.09.2023.pptx,
1. Epidemiology_Lecture_07.09.2023.pptx,1. Epidemiology_Lecture_07.09.2023.pptx,
1. Epidemiology_Lecture_07.09.2023.pptx,
GowthamSelvaraj21
 
Pandemic Covid 19 Series - Part 2
Pandemic Covid 19  Series - Part 2Pandemic Covid 19  Series - Part 2
Pandemic Covid 19 Series - Part 2
Salim Sheikh
 
Lakshita10 a
Lakshita10 aLakshita10 a
Lakshita10 a
LakshitaVyas1
 

Similar to Sars updates (20)

WHO_SARS_GLOBAL RESPONSE.ppt
WHO_SARS_GLOBAL RESPONSE.pptWHO_SARS_GLOBAL RESPONSE.ppt
WHO_SARS_GLOBAL RESPONSE.ppt
 
Yale ESF-8 Special Report COVID-19 3-26-2020
Yale ESF-8 Special Report COVID-19 3-26-2020Yale ESF-8 Special Report COVID-19 3-26-2020
Yale ESF-8 Special Report COVID-19 3-26-2020
 
Major Respritory Syndrom and COVID.pptx
Major Respritory Syndrom and COVID.pptxMajor Respritory Syndrom and COVID.pptx
Major Respritory Syndrom and COVID.pptx
 
SARS epidemiolody and morphology of the virus
SARS epidemiolody and morphology of the virusSARS epidemiolody and morphology of the virus
SARS epidemiolody and morphology of the virus
 
Emerging and re emerging diseases
Emerging and re emerging diseasesEmerging and re emerging diseases
Emerging and re emerging diseases
 
Coronavirus webinar ppt
Coronavirus webinar ppt Coronavirus webinar ppt
Coronavirus webinar ppt
 
Yale-Tulane-Sacred Heart- ESF-8 Special Global Report - COVID-19 4-27-20
Yale-Tulane-Sacred Heart- ESF-8 Special  Global Report - COVID-19 4-27-20 Yale-Tulane-Sacred Heart- ESF-8 Special  Global Report - COVID-19 4-27-20
Yale-Tulane-Sacred Heart- ESF-8 Special Global Report - COVID-19 4-27-20
 
Overview of COVID-19
Overview of COVID-19Overview of COVID-19
Overview of COVID-19
 
Yale-Tulane Special Report - MERS-CoV 26 APRIL 2014
Yale-Tulane Special Report  - MERS-CoV 26 APRIL 2014Yale-Tulane Special Report  - MERS-CoV 26 APRIL 2014
Yale-Tulane Special Report - MERS-CoV 26 APRIL 2014
 
120130 the sars experience
120130   the sars experience120130   the sars experience
120130 the sars experience
 
Epidemiology basic concepts,scope,uses, consideration, components ,history an...
Epidemiology basic concepts,scope,uses, consideration, components ,history an...Epidemiology basic concepts,scope,uses, consideration, components ,history an...
Epidemiology basic concepts,scope,uses, consideration, components ,history an...
 
SURVEILLANCE OF HEALTH EVENT
SURVEILLANCE OF HEALTH EVENTSURVEILLANCE OF HEALTH EVENT
SURVEILLANCE OF HEALTH EVENT
 
Yale- Tulane-Sacred Heart ESF-8 Special US Report - COVID-19 5-1-20
Yale- Tulane-Sacred Heart ESF-8 Special US Report - COVID-19  5-1-20Yale- Tulane-Sacred Heart ESF-8 Special US Report - COVID-19  5-1-20
Yale- Tulane-Sacred Heart ESF-8 Special US Report - COVID-19 5-1-20
 
Fight against SARS
Fight against SARS Fight against SARS
Fight against SARS
 
Week 4 Week 4 - Epidemiology—IntroductionEpidemiology—Introdu.docx
Week 4 Week 4 - Epidemiology—IntroductionEpidemiology—Introdu.docxWeek 4 Week 4 - Epidemiology—IntroductionEpidemiology—Introdu.docx
Week 4 Week 4 - Epidemiology—IntroductionEpidemiology—Introdu.docx
 
Lecture 1 epidemiology.pptx2222222222222
Lecture 1 epidemiology.pptx2222222222222Lecture 1 epidemiology.pptx2222222222222
Lecture 1 epidemiology.pptx2222222222222
 
Epidemic Investigation.pdf
Epidemic Investigation.pdfEpidemic Investigation.pdf
Epidemic Investigation.pdf
 
1. Epidemiology_Lecture_07.09.2023.pptx,
1. Epidemiology_Lecture_07.09.2023.pptx,1. Epidemiology_Lecture_07.09.2023.pptx,
1. Epidemiology_Lecture_07.09.2023.pptx,
 
Pandemic Covid 19 Series - Part 2
Pandemic Covid 19  Series - Part 2Pandemic Covid 19  Series - Part 2
Pandemic Covid 19 Series - Part 2
 
Lakshita10 a
Lakshita10 aLakshita10 a
Lakshita10 a
 

More from Dr. Manoj Kumbhare

The National Board of Accreditation (NBA)
The National Board of Accreditation (NBA)The National Board of Accreditation (NBA)
The National Board of Accreditation (NBA)
Dr. Manoj Kumbhare
 
Social and preventive Pharmacy UNIT 4.pptx
Social and preventive Pharmacy  UNIT 4.pptxSocial and preventive Pharmacy  UNIT 4.pptx
Social and preventive Pharmacy UNIT 4.pptx
Dr. Manoj Kumbhare
 
HMG-CoA reductase inhibitors.pptx
HMG-CoA reductase inhibitors.pptxHMG-CoA reductase inhibitors.pptx
HMG-CoA reductase inhibitors.pptx
Dr. Manoj Kumbhare
 
Calcium Channel Blockers.pptx
Calcium Channel Blockers.pptxCalcium Channel Blockers.pptx
Calcium Channel Blockers.pptx
Dr. Manoj Kumbhare
 
AUTOCOIDS.pptx
AUTOCOIDS.pptxAUTOCOIDS.pptx
AUTOCOIDS.pptx
Dr. Manoj Kumbhare
 
Antihypertensive Drugs.pptx
Antihypertensive Drugs.pptxAntihypertensive Drugs.pptx
Antihypertensive Drugs.pptx
Dr. Manoj Kumbhare
 
Drugs acting on ANS.ppt
Drugs acting on ANS.pptDrugs acting on ANS.ppt
Drugs acting on ANS.ppt
Dr. Manoj Kumbhare
 
Pharm.D. requirements
Pharm.D. requirements Pharm.D. requirements
Pharm.D. requirements
Dr. Manoj Kumbhare
 
Opportunities of BDS in Pharmaceutical Industries.pptx
Opportunities of BDS in Pharmaceutical Industries.pptxOpportunities of BDS in Pharmaceutical Industries.pptx
Opportunities of BDS in Pharmaceutical Industries.pptx
Dr. Manoj Kumbhare
 
Significance of Bioanalysis in drug discovery and development
Significance of Bioanalysis in drug discovery and developmentSignificance of Bioanalysis in drug discovery and development
Significance of Bioanalysis in drug discovery and development
Dr. Manoj Kumbhare
 
Bioanalysis significance 12 oct 2022.ppt
Bioanalysis significance 12 oct 2022.pptBioanalysis significance 12 oct 2022.ppt
Bioanalysis significance 12 oct 2022.ppt
Dr. Manoj Kumbhare
 
Oral hypoglycemic agents
Oral hypoglycemic agentsOral hypoglycemic agents
Oral hypoglycemic agents
Dr. Manoj Kumbhare
 
Nucleic acids
Nucleic acidsNucleic acids
Nucleic acids
Dr. Manoj Kumbhare
 
Gpat
GpatGpat
anti anginal
anti anginal anti anginal
anti anginal
Dr. Manoj Kumbhare
 
Role of enzymes in drug discovery
Role of enzymes in drug discoveryRole of enzymes in drug discovery
Role of enzymes in drug discovery
Dr. Manoj Kumbhare
 
Preparation for NAAC accreditation
Preparation for NAAC accreditationPreparation for NAAC accreditation
Preparation for NAAC accreditation
Dr. Manoj Kumbhare
 
Ethical issues in medical research
Ethical issues in medical researchEthical issues in medical research
Ethical issues in medical research
Dr. Manoj Kumbhare
 
Drug discovery short
Drug discovery shortDrug discovery short
Drug discovery short
Dr. Manoj Kumbhare
 
Calcium channel blockers
Calcium channel blockersCalcium channel blockers
Calcium channel blockers
Dr. Manoj Kumbhare
 

More from Dr. Manoj Kumbhare (20)

The National Board of Accreditation (NBA)
The National Board of Accreditation (NBA)The National Board of Accreditation (NBA)
The National Board of Accreditation (NBA)
 
Social and preventive Pharmacy UNIT 4.pptx
Social and preventive Pharmacy  UNIT 4.pptxSocial and preventive Pharmacy  UNIT 4.pptx
Social and preventive Pharmacy UNIT 4.pptx
 
HMG-CoA reductase inhibitors.pptx
HMG-CoA reductase inhibitors.pptxHMG-CoA reductase inhibitors.pptx
HMG-CoA reductase inhibitors.pptx
 
Calcium Channel Blockers.pptx
Calcium Channel Blockers.pptxCalcium Channel Blockers.pptx
Calcium Channel Blockers.pptx
 
AUTOCOIDS.pptx
AUTOCOIDS.pptxAUTOCOIDS.pptx
AUTOCOIDS.pptx
 
Antihypertensive Drugs.pptx
Antihypertensive Drugs.pptxAntihypertensive Drugs.pptx
Antihypertensive Drugs.pptx
 
Drugs acting on ANS.ppt
Drugs acting on ANS.pptDrugs acting on ANS.ppt
Drugs acting on ANS.ppt
 
Pharm.D. requirements
Pharm.D. requirements Pharm.D. requirements
Pharm.D. requirements
 
Opportunities of BDS in Pharmaceutical Industries.pptx
Opportunities of BDS in Pharmaceutical Industries.pptxOpportunities of BDS in Pharmaceutical Industries.pptx
Opportunities of BDS in Pharmaceutical Industries.pptx
 
Significance of Bioanalysis in drug discovery and development
Significance of Bioanalysis in drug discovery and developmentSignificance of Bioanalysis in drug discovery and development
Significance of Bioanalysis in drug discovery and development
 
Bioanalysis significance 12 oct 2022.ppt
Bioanalysis significance 12 oct 2022.pptBioanalysis significance 12 oct 2022.ppt
Bioanalysis significance 12 oct 2022.ppt
 
Oral hypoglycemic agents
Oral hypoglycemic agentsOral hypoglycemic agents
Oral hypoglycemic agents
 
Nucleic acids
Nucleic acidsNucleic acids
Nucleic acids
 
Gpat
GpatGpat
Gpat
 
anti anginal
anti anginal anti anginal
anti anginal
 
Role of enzymes in drug discovery
Role of enzymes in drug discoveryRole of enzymes in drug discovery
Role of enzymes in drug discovery
 
Preparation for NAAC accreditation
Preparation for NAAC accreditationPreparation for NAAC accreditation
Preparation for NAAC accreditation
 
Ethical issues in medical research
Ethical issues in medical researchEthical issues in medical research
Ethical issues in medical research
 
Drug discovery short
Drug discovery shortDrug discovery short
Drug discovery short
 
Calcium channel blockers
Calcium channel blockersCalcium channel blockers
Calcium channel blockers
 

Recently uploaded

Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 

Recently uploaded (20)

Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 

Sars updates

  • 1. Reporting Incidence of Severe Acute Respiratory Syndrome (SARS)
  • 2. What is SARS? • Definition: – “Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a coronavirus, called SARS-associated coronavirus (SARS-CoV).” • Symptoms: – high fever (> 100.4°F/ 38.0°C) at outset with – headache, overall feeling of discomfort, & body aches – some experience mild respiratory symptoms, diarrhea, & dry cough. – most develop pneumonia. Source: US Center for Disease Control and Prevention SARS Factsheet
  • 3. A Global Context • Outbreaks of infectious diseases can attain epidemic proportions in many countries more quickly than in previous centuries. – Increased speed of travel – Larger numbers of travelers • Thus, limiting the spread of infectious diseases requires a *joint effort*
  • 4. Controlling Spread of Disease • Success requires that governments: – identify outbreaks of an infectious disease soon after the initial cases appear – isolate persons who have the disease or have been in close contact with others having the disease until they are no longer contagious – minimize the number of non-infected persons who come in contact with currently infected persons or any place where germs are likely to be present – warn other governments so they can take action to ward off spread to their countries
  • 5. The World Health Organization • “the directing and coordinating authority for health within the United Nations system. It is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries and monitoring and assessing health trends.” WHO Website (emphasis added) • in 2002-2003, WHO authority to address outbreaks was based on the International Health Regulations of 1969
  • 6. International Health Regulations of 1969 • Regulated international cooperation to prevent spread of disease – BUT did not give the WHO any enforcement powers • Required reporting outbreaks of infectious diseases – BUT only specifically listed diseases, not any new disease likely to spread • Established a system of mutual assistance so that all states could get help from WHO in identifying causes of infection and developing methods of treatment – BUT states were not obliged to let WHO teams visit disease- stricken areas or have their medical labs participate in collaborative work.
  • 7. The Outbreak Map from Bill Marsh, The New York Times, 2003 8,141 cases in 31 countries resulting in 769 deaths at a cost of $40 billion worldwide in lost trade and tourism
  • 8. National Responses Compare and contrast: • the slow and private actions of China • the immediate actions of Vietnam • the very public and cautious actions of Canada as shown on the next few slides.
  • 9. SARS in China • November 2002: Identifies “atypical pneumonia” • February 14, 2003: Reports 305 cases and 5 deaths to WHO; claims spread is under control • February 18, 2003: Dr. Hong Tao concludes that the new disease is a variant of the chlamydia virus • February 20, 2003: Chinese Academy of Military Medical Sciences (AMMS) researchers believe Tao’s theory is wrong; decide to conduct further research before making public statements • February 21, 2003: Chinese SARS-treating doctor travels to Hong Kong hotel; infects other guests • early March, 2003: AMMS scientists find additional support for coronavirus; again decide to continue research before criticizing Government acceptance of Tao’s theory Continued….
  • 10. SARS in China • March 10, 2003: Health Ministry requests WHO assistance • March 21, 2003: AMMS publicly reports findings to Army Logistical Department and Ministry of Health • March 21, 2003: Health Ministry requests additional WHO assistance; WHO sends 5 people • March 25, 2003: WHO team is barred from Guangdong Province • March 27, 2003: Guangdong Province issues guidelines on community prevention and control • March 28, 2003: Health Ministry grees to work with WHO • April 3, 2003: Health Ministry allows WHO teams to visit infected sites • May 13, 2003: CNN International special on SARS that criticized the Chinese government’s response to the illness is censored in China • End result: 7,083 cases and 644 deaths
  • 11. SARS in Vietnam • February 26, 2003: First case identified • February 26, 2003: Asks for WHO assistance; WHO sends team • March 6, 2003: USA sends team from Center for Disease Control • April 29, 2003: SARS declared contained in Vietnam • End result: 63 cases and 5 deaths
  • 12. SARS in Canada • November 27, 2002: Canadian Global Public Health Intelligence Network (GPHIN) relays media reports of atypical pneumonia in Guangdong Province to WHO Global Influenza Surveillance Network • January 21, 2003: GPHIN Report is translated to English • March 5, 2003: First case identified in Toronto • March 17, 2003: Health Canada announces 11 cases of SARS • April 11, 2003: Canadian Blood Services refuses donations from persons who have been to Southeast Asia recently (even though there is no evidence of bloodstream transfers of SARS infection) • April 13, 2003: Michael Smith Genome Sciences Centre posts SARS genome sequence online • April 20, 2003: Canada's largest trauma unit stops accepting new patients after at least four health-care workers show signs of SARS Continued…
  • 13. SARS in Canada • April 23, 2003: WHO extends travel warnings to Toronto for 3 weeks, double the incubation time of SARS • May 1, 2003: WHO's director of communicable-disease surveillance and response writes an opinion article saying that the Toronto travel advisory could ultimately harm the fight against SARS because less- transparent countries will be afraid to report outbreaks, fearing economic costs. • May 14, 2003: Canada removed from WHO list of SARS-affected countries • May 24, 2003: Reports of new SARS cases; state of emergency declared in Ontario; More than 500 people ordered into quarantine in Toronto • July 2, 2003: WHO removes Toronto from list of SARS affected areas • End result: 251 cases and 43 deaths
  • 14. Discussion • China, Canada and Vietnam dealt with the spread of SARS in very different ways. Consider each country’s approach when answering the following questions: – Where did international regulations break down? Where did they work? • How would you redesign an international reporting system? – Who asked for cooperation and who did not? • What arguments did countries use support their decisions to, or not to, cooperate with the WHO and other governments? – What would you have done the same or differently • As a bench scientist in China? in Canada? • As a managing health official in China? in Canada? – Who is to blame for allowing SARS to spread as far as it did?